^
    1d
    A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    1d
    Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (clinicaltrials.gov)
    P2, N=236, Not yet recruiting, Sun Yat-sen University
    New P2 trial • Head-to-Head
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    2d
    concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Zhejiang University
    New P2 trial • Checkpoint inhibition • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    3d
    A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (clinicaltrials.gov)
    P3, N=703, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • Fruzaqla (fruquintinib)
    15d
    A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Kahr Bio Australia Pty Ltd
    New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    Tecentriq (atezolizumab) • Fruzaqla (fruquintinib) • DSP-107
    17d
    A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Harbin Medical University
    New P2 trial • pMMR
    |
    Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    1m
    Efficacy and Safety of QL1706 combined with Regorafenib or Fruquintinib as Third-Line Therapy for Advanced Colorectal Cancer (ChiCTR2500110556)
    P4, N=26, Not yet recruiting, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial
    |
    Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Qibeian (iparomlimab/tuvonralimab)
    1m
    Fruquintinib in combination with TAS-102 versus bevacizumab in combination with TAS-102 in the third line and later for the treatment of advanced metastatic CRC Non-randomized controlled, single-center, retrospective, cohort study (ChiCTR2500110400)
    P=N/A, N=80, Recruiting, Ningbo No.2 Hospital; Ningbo No.2 Hospital
    New trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    1m
    A Phase II clinical study of Fruquintinib in the treatment of advanced or unresectable soft tissue sarcomas that have failed prior antiangiogenic therapy or chemotherapy (ChiCTR2500109087)
    P4, N=50, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P4 trial
    |
    Fruzaqla (fruquintinib)
    1m
    Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=102, Recruiting, Barbara Ann Karmanos Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    2ms
    Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1/2, N=67, Active, not recruiting, Immunitas Therapeutics | Recruiting --> Active, not recruiting | N=151 --> 67 | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2025 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability)
    |
    BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation • HER-2 overexpression + HR positive
    |
    Fruzaqla (fruquintinib) • IMT-009
    2ms
    HMPL-013-FLAG-G103: Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Henan Cancer Hospital | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • oxaliplatin • Fruzaqla (fruquintinib)